Acute myeloid leukemia following icotinib therapy for non-small cell lung cancer: a case report and literature review
- 1Department of Pharmacy, Wuhan Asia General Hospital
- 2Department of Pharmacy, Liyuan Hospital of Tongji Medical College of Huazhong University of Science & Technology
- 3Department of Oncology, Wuhan Asia General Hospital
Abstract
Icotinib significantly improves survival and prognosis in patients with epidermal growth factor receptor (EGFR)-sensitive non-small cell lung cancer (NSCLC). It is generally well-tolerated, with treatment-related myeloid neoplasm (t-MN) being a rare adverse reaction. We report a case of a 75-year-old female patient with lung adenocarcinoma (EGFR exon 21 L858R mutation) who underwent four cycles of pemetrexed combined with platinum-based chemotherapy postoperatively, followed by radiation therapy to the supraclavicular and mediastinal lymphatic drainage regions, and sequential targeted therapy with icotinib. Approximately 32 months after initiating icotinib, the patient developed severe anemia, leading to discontinuation of the drug. She was subsequently diagnosed with acute myeloid leukemia (AML) and treated with a regimen of lisaftoclax combined with azacitidine; bone marrow examination after one cycle of treatment showed partial remission. The patient later experienced relapse and progression of AML and died 4 months after the AML diagnosis. We also reviewed previous cases of t-MN induced during treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Based on this literature review, it remains unclear whether EGFR-TKIs are independent risk factors for t-MN. This study suggests that patients with NSCLC receiving EGFR-TKIs should undergo long-term, regular monitoring of complete blood counts. Clinicians should be vigilant for the risk of t-MN in patients with persistent cytopenia and should identify such cases and intervene as early as possible.
Related
- Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review
- Therapy-related T-lymphoblastic lymphoma following acute myeloid leukemia remission with IDH2 mutation persistence
- Infection Profiles Under Venetoclax‐Based Therapy in Newly Diagnosed Acute Myeloid Leukemia: A Real‐World Study
- Efficacy of Sorafenib Combined with Venetoclax and Azacitidine in Newly Diagnosed FLT3-ITD-Mutant Acute Myeloid Leukemia: Remission Efficacy and Prognostic Influence of Post-Remission Consolidation Therapy
- Sorafenib-Induced Hand-Foot Skin Reaction in a Patient With Acute Myeloid Leukemia Following Haploidentical Stem Cell Transplantation: A Case Report.
BibTeX
@article{huang2026acute,
title = {{Acute myeloid leukemia following icotinib therapy for non-small cell lung cancer: a case report and literature review}},
author = {Huiling Huang and Lu Song and Fangqin Tong and Lei Li},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1967553},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1967553/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Acute myeloid leukemia following icotinib therapy for non-small cell lung cancer: a case report and literature review
AU - Huiling Huang
AU - Lu Song
AU - Fangqin Tong
AU - Lei Li
PY - 2026
DA - 2026/10/22
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1967553
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1967553/full
AB - Icotinib significantly improves survival and prognosis in patients with epidermal growth factor receptor (EGFR)-sensitive non-small cell lung cancer (NSCLC). It is generally well-tolerated, with treatment-related myeloid neoplasm (t-MN) being a rare adverse reaction. We report a case of a 75-year-old female patient with lung adenocarcinoma (EGFR exon 21 L858R mutation) who underwent four cycles of pemetrexed combined with platinum-based chemotherapy postoperatively, followed by radiation therapy to the supraclavicular and mediastinal lymphatic drainage regions, and sequential targeted therapy with icotinib. Approximately 32 months after initiating icotinib, the patient developed severe anemia, leading to discontinuation of the drug. She was subsequently diagnosed with acute myeloid leukemia (AML) and treated with a regimen of lisaftoclax combined with azacitidine; bone marrow examination after one cycle of treatment showed partial remission. The patient later experienced relapse and progression of AML and died 4 months after the AML diagnosis. We also reviewed previous cases of t-MN induced during treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). Based on this literature review, it remains unclear whether EGFR-TKIs are independent risk factors for t-MN. This study suggests that patients with NSCLC receiving EGFR-TKIs should undergo long-term, regular monitoring of complete blood counts. Clinicians should be vigilant for the risk of t-MN in patients with persistent cytopenia and should identify such cases and intervene as early as possible.
SN - 2234-943X
ER -